Ukrainian Journal Health of Woman. 2026. 2(183): 92-96. doi: 10.15574/HW.2026.2(183).9296
Kopchuk T. H.
Bukovinian State Medical University, Chernivtsi, Ukraine

For citation: Kopchuk TH. (2026). Pharmacotherapy of postpartum hemorrhage: modern evidence-based approaches. Ukrainian Journal Health of Woman. 2(183): 92-96. doi: 10.15574/HW.2026.2(183).9296
Article received: Jan 07, 2026. Accepted for publication: Mar 22, 2026.

Postpartum hemorrhage (PPH) remains one of the main causes of maternal morbidity and mortality in the world. Timely pharmacotherapy is a key element of complex treatment, which contributes to reducing the risk of serious complications and fatal consequences. Modern international recommendations provide for the early use of uterotonic drugs, antifibrinolytic therapy and the individualized choice of medical treatment depending on the etiology of bleeding; however, the results of the latest research require systematization and generalization.
Aim – to conduct a systematic analysis of modern scientific data on the effectiveness, safety and evidence base of pharmacotherapy of PPH, as well as to determine modern approaches to drug treatment in accordance with international clinical recommendations.
Early use of uterotonic drugs, primarily oxytocin, is the basis of medical treatment of PPH. In case of insufficient efficiency, carbetocin, methylergometrine, prostaglandins, and misoprostol are used, taking into account the clinical situation. Early administration of tranexamic acid within the first three hours after bleeding has been shown to reduce the risk of maternal mortality. The effectiveness of pharmacotherapy depends on timely diagnosis, adherence to clinical protocols and the combination of drug treatment with other methods of emergency obstetric care.
Conclusions. A systematic analysis of modern scientific data confirms that pharmacotherapy is a defining component of the complex treatment of PPH. Early use of oxytocin as a first-line drug, timely administration of tranexamic acid, and use of alternative uterotonic agents according to the clinical situation are the most justified from the standpoint of evidence-based medicine.
The author declares no conflict of interest.
Keywords: postpartum bleeding, pharmacotherapy, oxytocin, tranexamic acid, uterotonic drugs, evidence-based medicine.

REFERENCES

1. Ammerdorffer A, Rushwan S, Timms R, Wright P, Beeson L, Devall AJ et al. (2022, Jun). Quality of oxytocin and tranexamic acid for the prevention and treatment of postpartum hemorrhage in Kenya, Nigeria, South Africa, and Tanzania. Int J Gynaecol Obstet. 158; Suppl 1: 46-55. https://doi.org/10.1002/ijgo.14197; PMid:35762808 PMCid:PMC9543376

2. Bienstock JL, Eke AC, Hueppchen NA. (2021, Apr 29). Postpartum Hemorrhage. N Engl J Med. 384(17): 1635-1645. https://doi.org/10.1056/NEJMra1513247; PMid:33913640 PMCid:PMC10181876

3. Brenner A, Ker K, Shakur-Still H, Roberts I. (2019, Nov). Tranexamic acid for post-partum haemorrhage: What, who and when. Best Pract Res Clin Obstet Gynaecol. 61: 66-74. https://doi.org/10.1016/j.bpobgyn.2019.04.005; PMid:31128974 PMCid:PMC6891248

4. De Silva M, Mizzi G, Potts E, Webb J, Thyer E, Naidoo N. (2024, Apr). Tranexamic acid versus oxytocin for primary postpartum Haemorrhage in the out-of-hospital setting: A systematic review with implications for rural practice. Aust J Rural Health. 32(2): 227-235. https://doi.org/10.1111/ajr.13103; PMid:38491718

5. Diop A, Abbas D, Ngoc NTN, Martin R, Razafi A et al. (2020, Mar 6). A double-blind, randomized controlled trial to explore oral tranexamic acid as adjunct for the treatment for postpartum hemorrhage. Reprod Health. 17(1): 34. https://doi.org/10.1186/s12978-020-0887-2; PMid:32143721 PMCid:PMC7060559

6. Ducloy-Bouthors AS, Jude B, Duhamel A, Broisin F, Huissoud C, Keita-Meyer H et al. (2011). Mandelbr High-dose tranexamic acid reduces blood loss in postpartum haemorrhage. Crit Care. 15(2): R117. https://doi.org/10.1186/cc10143; PMid:21496253 PMCid:PMC3219400

7. Elbohoty AE, Mohammed WE, Sweed M, Bahaa Eldin AM et al. (2016, Sep). Randomized controlled trial comparing carbetocin, misoprostol, and oxytocin for the prevention of postpartum hemorrhage following an elective cesarean delivery. Int J Gynaecol Obstet. 134(3): 324-328. https://doi.org/10.1016/j.ijgo.2016.01.025; PMid:27350226

8. Gallos ID, Papadopoulou A, Man R, Athanasopoulos N, Tobias A, Price MJ et al. (2018, Dec 19). Uterotonic agents for preventing postpartum haemorrhage: a network meta-analysis. Cochrane Database Syst Rev. 12(12): CD011689. doi: 10.1002/14651858.CD011689.pub3. Update in: Cochrane Database Syst Rev. 2025 Apr 16; 4: CD011689. https://doi.org/10.1002/14651858.CD011689.pub4; PMid:40237648 PMCid:PMC12002006

9. Giouleka S, Tsakiridis I, Kalogiannidis I, Mamopoulos A, Tentas I et al. (2022, Nov). Postpartum Hemorrhage: A Comprehensive Review of Guidelines. Obstet Gynecol Surv. 77(11): 665-682. https://doi.org/10.1097/OGX.0000000000001061; PMid:36345105

10. Günaydın B. (2022, Dec). Management of Postpartum Haemorrhage. Turk J Anaesthesiol Reanim. 50(6): 396-402. https://doi.org/10.5152/TJAR.2022.21438; PMid:36511487 PMCid:PMC9885818

11. Jones AJ, Federspiel JJ, Eke AC. (2023, Feb). Preventing postpartum hemorrhage with combined therapy rather than oxytocin alone. Am J Obstet Gynecol MFM. 5(2S): 100731. https://doi.org/10.1016/j.ajogmf.2022.100731; PMid:36028160 PMCid:PMC9941051

12. Koch DM, Rattmann YD. (2019, Nov 7). Use of misoprostol in the treatment of postpartum hemorrhage: a pharmacoepidemiological approach. Einstein (Sao Paulo). 18: eAO5029. https://doi.org/10.31744/einstein_journal/2020AO5029; PMid:31721897 PMCid:PMC6896658

13. Pacheco LD, Clifton RG, Saade GR, Weiner SJ, Parry S, Thorp JM Jr et al. (2023, Apr 13). Tranexamic Acid to Prevent Obstetrical Hemorrhage after Cesarean Delivery. N Engl J Med. 388(15): 1365-1375. https://doi.org/10.1056/NEJMoa2207419; PMid:37043652 PMCid:PMC10200294

14. Parry Smith WR, Papadopoulou A, Thomas E, Tobias A, Price MJ, Meher S et al. (2020, Nov 24). Uterotonic agents for first-line treatment of postpartum haemorrhage: a network meta-analysis. Cochrane Database Syst Rev. 11(11): CD012754. https://doi.org/10.1002/14651858.CD012754.pub2; PMid:33232518 PMCid:PMC8130992

15. Sentilhes L, Vayssière C, Deneux-Tharaux C, Aya AG, Bayoumeu F, Bonnet MP et al. (2016, Mar). Postpartum hemorrhage: guidelines for clinical practice from the French College of Gynaecologists and Obstetricians (CNGOF): in collaboration with the French Society of Anesthesiology and Intensive Care (SFAR). Eur J Obstet Gynecol Reprod Biol. 198: 12-21. https://doi.org/10.1016/j.ejogrb.2015.12.012; PMid:26773243

16. Sentilhes L, Winer N, Azria E, Sénat MV, Le Ray C, Vardon D et al. (2018, Aug 23). Tranexamic Acid for the Prevention of Blood Loss after Vaginal Delivery. N Engl J Med. 379(8): 731-742. https://doi.org/10.1056/NEJMoa1800942; PMid:30134136

17. Torloni MR, Siaulys M, Riera R, Cabrera Martimbianco AL, Leite Pacheco R, Latorraca COC et al. (2021, Jun 3). Timing of oxytocin administration to prevent post-partum hemorrhage in women delivered by cesarean section: A systematic review and metanalysis. PLoS One. 16(6): e0252491. https://doi.org/10.1371/journal.pone.0252491; PMid:34081734 PMCid:PMC8174699

18. Vallera C, Choi LO, Cha CM, Hong RW. (2017, Jun). Uterotonic Medications: Oxytocin, Methylergonovine, Carboprost, Misoprostol. Anesthesiol Clin. 35(2): 207-219. https://doi.org/10.1016/j.anclin.2017.01.007; PMid:28526143

19. Winikoff B, Dabash R, Durocher J, Darwish E, Nguyen TN, León W et al. (2010, Jan 16). Treatment of post-partum haemorrhage with sublingual misoprostol versus oxytocin in women not exposed to oxytocin during labour: a double-blind, randomised, non-inferiority trial. Lancet. 375(9710): 210-216. https://doi.org/10.1016/S0140-6736(09)61924-3; PMid:20060161

20. Wormer KC, Jamil RT, Bryant SB. (2024, Jul 19). Postpartum Hemorrhage. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan-. PMID: 29763164.